RegulatoryCompany release

Revolution Medicines books $197.6m from first RASONQUE sales as CHMP backs EU approval

🇺🇸 Revolution Medicines, Inc. (RVMD) · Wed 04 Nov 2026

The US launch of daraxonrasib in previously treated metastatic pancreatic adenocarcinoma brought in $197.6m in roughly five weeks, while a European Commission decision is still pending.

Revolution Medicines reported third-quarter 2026 results on 4 November, disclosing net product revenue of $197.6 million for RASONQUE (daraxonrasib). The sales followed the drug's US approval and covered a period of about five weeks.

The US Food and Drug Administration approved RASONQUE on 26 August for patients with previously treated metastatic pancreatic adenocarcinoma.

In Europe, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion in October for the same indication. A European Commission decision has not yet been made.

As general context, a positive CHMP opinion is a recommendation rather than a marketing authorisation. The Commission normally issues the legally binding decision after the opinion.

What it means for your team

  • Market-access teams should note the rapid US uptake figure as an early reference point for a new second-line pancreatic cancer therapy.
  • Regulatory teams in Europe should watch for the European Commission decision, which is the step that would turn the CHMP opinion into an EU authorisation.
  • Pharmacovigilance teams may need to prepare for post-approval safety monitoring as real-world use of RASONQUE grows in the US.

Company's press release (SEC filing): Revolution Medicines, Inc. ↗

Article written by VigiEye from the official source (Revolution Medicines, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Regulatory All →